These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
295 related articles for article (PubMed ID: 17188136)
1. Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression. Saltman B; Singh B; Hedvat CV; Wreesmann VB; Ghossein R Surgery; 2006 Dec; 140(6):899-905; discussion 905-6. PubMed ID: 17188136 [TBL] [Abstract][Full Text] [Related]
2. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas. Soda G; Antonaci A; Bosco D; Nardoni S; Melis M J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183 [TBL] [Abstract][Full Text] [Related]
3. Expression profile of biomarkers altered in papillary and anaplastic thyroid carcinoma: Contribution of Tunisian patients. Fourati A; El Amine O; Ben Ayoub W; Cherni I; Goucha A; El May MV; Gamoudi A; El May A Bull Cancer; 2017 May; 104(5):433-441. PubMed ID: 28185633 [TBL] [Abstract][Full Text] [Related]
4. RASSF10 is Epigenetically Inactivated and Suppresses Cell Proliferation and Induces Cell Apoptosis by Activating the p53 Signalling Pathway in Papillary Thyroid Carcinoma Cancer. Fan C; Wang W; Jin J; Yu Z; Xin X Cell Physiol Biochem; 2017; 41(3):1229-1239. PubMed ID: 28268222 [TBL] [Abstract][Full Text] [Related]
5. A comparative study of cell cycle mediator protein expression patterns in anaplastic and papillary thyroid carcinoma. Evans JJ; Crist HS; Durvesh S; Bruggeman RD; Goldenberg D Cancer Biol Ther; 2012 Jul; 13(9):776-81. PubMed ID: 22688732 [TBL] [Abstract][Full Text] [Related]
6. Changes in the expression pattern of apoptotic molecules (galectin-3, Bcl-2, Bax, survivin) during progression of thyroid malignancy and their clinical significance. Selemetjev SA; Savin SB; Paunovic IR; Tatic SB; Cvejic D Wien Klin Wochenschr; 2015 May; 127(9-10):337-44. PubMed ID: 25471003 [TBL] [Abstract][Full Text] [Related]
7. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523 [TBL] [Abstract][Full Text] [Related]
9. The role of survivin in thyroid tumors: differences of expression in well-differentiated, non-well-differentiated, and anaplastic thyroid cancers. Pannone G; Santoro A; Pasquali D; Zamparese R; Mattoni M; Russo G; Landriscina M; Piscazzi A; Toti P; Cignarelli M; Lo Muzio L; Bufo P Thyroid; 2014 Mar; 24(3):511-9. PubMed ID: 24117205 [TBL] [Abstract][Full Text] [Related]
10. p53, p16 and cyclin D1: molecular determinants of radiotherapy treatment response in oral carcinoma. Jayasurya R; Francis G; Kannan S; Lekshminarayanan K; Nalinakumari KR; Abraham T; Abraham EK; Nair MK Int J Cancer; 2004 May; 109(5):710-6. PubMed ID: 14999779 [TBL] [Abstract][Full Text] [Related]
11. Cell cycle regulators show diagnostic and prognostic utility for differentiated thyroid cancer. Melck A; Masoudi H; Griffith OL; Rajput A; Wilkins G; Bugis S; Jones SJ; Wiseman SM Ann Surg Oncol; 2007 Dec; 14(12):3403-11. PubMed ID: 17882495 [TBL] [Abstract][Full Text] [Related]
12. The maintenance of hippocampal pyramidal neuron populations is dependent on the modulation of specific cell cycle regulators by thyroid hormones. Alva-Sánchez C; Sánchez-Huerta K; Arroyo-Helguera O; Anguiano B; Aceves C; Pacheco-Rosado J Brain Res; 2009 May; 1271():27-35. PubMed ID: 19269280 [TBL] [Abstract][Full Text] [Related]
13. Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma. Schwertheim S; Sheu SY; Worm K; Grabellus F; Schmid KW Horm Metab Res; 2009 Jun; 41(6):475-81. PubMed ID: 19370508 [TBL] [Abstract][Full Text] [Related]
14. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Pfister C; Moore L; Allard P; Larue H; Lacombe L; Têtu B; Meyer F; Fradet Y Clin Cancer Res; 1999 Dec; 5(12):4079-84. PubMed ID: 10632343 [TBL] [Abstract][Full Text] [Related]
15. Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma. Nikitski AV; Rominski SL; Condello V; Kaya C; Wankhede M; Panebianco F; Yang H; Altschuler DL; Nikiforov YE Thyroid; 2019 Oct; 29(10):1425-1437. PubMed ID: 31298630 [No Abstract] [Full Text] [Related]
16. The role of cell cycle regulatory protein, cyclin D1, in the progression of thyroid cancer. Wang S; Lloyd RV; Hutzler MJ; Safran MS; Patwardhan NA; Khan A Mod Pathol; 2000 Aug; 13(8):882-7. PubMed ID: 10955455 [TBL] [Abstract][Full Text] [Related]
17. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1 in colorectal carcinoma: correlation with other cell cycle regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological features. Ioachim E Int J Clin Pract; 2008 Nov; 62(11):1736-43. PubMed ID: 19143860 [TBL] [Abstract][Full Text] [Related]
18. Expression patterns of cyclins D1, E and cyclin-dependent kinase inhibitors p21(Waf1/Cip1) and p27(Kip1) in urothelial carcinoma: correlation with other cell-cycle-related proteins (Rb, p53, Ki-67 and PCNA) and clinicopathological features. Ioachim E; Michael M; Stavropoulos NE; Kitsiou E; Hastazeris K; Salmas M; Stefanaki S; Agnantis NJ Urol Int; 2004; 73(1):65-73. PubMed ID: 15263796 [TBL] [Abstract][Full Text] [Related]
19. Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder. Yurakh AO; Ramos D; Calabuig-Fariñas S; López-Guerrero JA; Rubio J; Solsona E; Romanenko AM; Vozianov AF; Pellin A; Llombart-Bosch A Eur Urol; 2006 Sep; 50(3):506-15; discussion 515. PubMed ID: 16624482 [TBL] [Abstract][Full Text] [Related]